Dr. Thomas A. Hensing, MD

Dr. Hensing practices at Swedish Hospital in Chicago, Illinois, part of Endeavor Health.

Dr. Hensing's NPI, 1932132743, was assigned on July 8, 2006. Dr. Hensing graduated from University of Maryland School of Medicine - Baltimore in 1994. Dr. Hensing holds Illinois license 036108667.

Dr. Hensing's primary practice is Swedish Hospital, at 5145 N California Ave, Chicago, IL 60625 in Cook County. The practice phone is (773) 878-8200.

Dr. Hensing's primary practice is Swedish Hospital in Chicago, Illinois, part of Endeavor Health. Dr. Hensing is also affiliated with Evanston Hospital. The medical group on file is Endeavor Health Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hensing practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Hensing's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Hensing is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Hensing's licenses on file in 2 states: Illinois and North Carolina.

Dmand AI lists breast cancer, chronic leukemia, lung cancer and prostate cancer among the conditions Dr. Hensing treats.

CMS data shows 632 Medicare services from Dr. Hensing across 6 procedure codes in 2024, for 141 Medicare patients. Medicare paid $38,460 for them.

CMS counts 141 Medicare patients who saw Dr. Hensing in 2024. The largest group is 75 to 84, with 61 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hensing's median patient age at 75, with 60% women.

In 2024, Dr. Hensing wrote 241 Medicare Part D claims for 48 patients. 74% of them were for generic drugs. CMS names the drug for 159 of them, across 6 drugs with 11 or more claims each, at $883,816 in total drug cost. In 2023, CMS named 164 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Hensing for performance year 2024, reported as part of a group. Dr. Hensing accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hensing as offering telehealth.

Dmand AI links 67 papers to Dr. Hensing, published from 2005 to 2022. 2014 was the busiest year, with 6. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Hensing has published most often in J Thorac Oncol. Dr. Hensing's most frequent co-authors are Mark A. Socinski, MD, Mark K. Ferguson and Thomas E. Stinchcombe, MD.

Dmand AI links Dr. Hensing to 13 clinical trials, 5 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. National Cancer Institute (NCI) sponsors the most, 7.

CMS Open Payments shows 36 general payments to Dr. Hensing from 8 drug and device companies from 2016 to 2020. Consulting fees make up the largest share, 61% of the total. AstraZeneca Pharmaceuticals LP paid the most, $19,767.

Dmand AI lists 3 awards for Dr. Hensing, most recently Regional Top Doctor in 2014.

Dr. Hensing graduated from University of Maryland School of Medicine - Baltimore in 1994. Dr. Hensing is a member of ASCO.

Dr. Hensing is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.